Related Experiment Video

Updated: May 29, 2026

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
04:11

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Published on: December 15, 2023

Redefining baseline demographics: the role of genetic testing in hepatitis C virus infection

Jacinta A Holmes1, Paul V Desmond, Alexander J Thompson

  • 1Department of Gastroenterology and Hepatology, St Vincent's Hospital, 41 Victoria Parade, Fitzroy 3065, Victoria, Australia.

Clinics in Liver Disease
|August 27, 2011
PubMed

Insights

Identifying genetic variants like IL28B and ITPA can help personalize hepatitis C virus (HCV) treatment. This improves patient outcomes for the common genotype 1 HCV infection, addressing limitations of current therapies.

Area of Science:

  • Hepatology
  • Virology
  • Genetics

Background:

  • Current standard treatment for hepatitis C virus (HCV) infection, pegylated interferon and ribavirin, has limited efficacy (40-50% cure rate) for genotype 1.
  • This treatment is costly and poorly tolerated, necessitating better patient selection for antiviral therapy.

Purpose of the Study:

  • To identify genetic factors that predict treatment response in patients with HCV infection.
  • To enhance the personalization of antiviral therapy for HCV based on genetic profiles.

Main Methods:

  • Genome-wide association studies (GWAS) were employed to identify genetic variants associated with treatment outcomes.
  • Focus was placed on specific genetic markers, including IL28B and ITPA.

Main Results:

  • Genome-wide association studies identified significant genetic variants, notably IL28B and ITPA.
  • These genetic variants are associated with predicting patient response to antiviral therapy for HCV.

Conclusions:

  • Genetic variants such as IL28B and ITPA play a crucial role in personalizing HCV treatment.
  • Identifying these markers can improve the efficacy and tolerability of antiviral therapy, optimizing patient care for hepatitis C.

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...